Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Mar;17 Suppl 2(Suppl 2):ii24-ii36.
doi: 10.1093/neuonc/nou355.

Sui generis: gene therapy and delivery systems for the treatment of glioblastoma

J Robert Kane  1 , Jason Miska  1 , Jacob S Young  1 , Deepak Kanojia  1 , Julius W Kim  1 , Maciej S Lesniak  1
Affiliations
Review

Sui generis: gene therapy and delivery systems for the treatment of glioblastoma

J Robert Kane et al. Neuro Oncol. 2015 Mar.

Abstract

Gene therapy offers a multidimensional set of approaches intended to treat and cure glioblastoma (GBM), in combination with the existing standard-of-care treatment (surgery and chemoradiotherapy), by capitalizing on the ability to deliver genes directly to the site of neoplasia to yield antitumoral effects. Four types of gene therapy are currently being investigated for their potential use in treating GBM: (i) suicide gene therapy, which induces the localized generation of cytotoxic compounds; (ii) immunomodulatory gene therapy, which induces or augments an enhanced antitumoral immune response; (iii) tumor-suppressor gene therapy, which induces apoptosis in cancer cells; and (iv) oncolytic virotherapy, which causes the lysis of tumor cells. The delivery of genes to the tumor site is made possible by means of viral and nonviral vectors for direct delivery of therapeutic gene(s), tumor-tropic cell carriers expressing therapeutic gene(s), and "intelligent" carriers designed to increase delivery, specificity, and tumoral toxicity against GBM. These vehicles are used to carry genetic material to the site of pathology, with the expectation that they can provide specific tropism to the desired site while limiting interaction with noncancerous tissue. Encouraging preclinical results using gene therapies for GBM have led to a series of human clinical trials. Although there is limited evidence of a therapeutic benefit to date, a number of clinical trials have convincingly established that different types of gene therapies delivered by various methods appear to be safe. Due to the flexibility of specialized carriers and genetic material, the technology for generating new and more effective therapies already exists.

Keywords: delivery vehicles; gene therapy; glioblastoma; immunomodulatory therapy; oncolytic virotherapy.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Examples, advantages, and limitations of suicide gene therapy.
Fig. 2.
Fig. 2.
Examples, advantages, and limitations of immunomodulatory gene therapy.
Fig. 3.
Fig. 3.
Examples, advantages, and limitations of tumor-suppressor gene therapy.
Fig. 4.
Fig. 4.
Examples, advantages, and limitations of oncolytic virotherapy.
See this image and copyright information in PMC

References

    1. Grossman SA, Ye X, Piantadosi S, et al. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin Cancer Res. 2010;16(8):2443–2449. - PMC - PubMed
    1. Kay MA, Glorioso JC, Naldini L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med. 2001;7(1):33–40. - PubMed
    1. Friedmann T, Roblin R. Gene therapy for human genetic disease? Science. 1972;175(4025):949–955. - PubMed
    1. Fischer U, Steffens S, Frank S, et al. Mechanisms of thymidine kinase/ganciclovir and cytosine deaminase/5-fluorocytosine suicide gene therapy-induced cell death in glioma cells. Oncogene. 2005;24(7):1231–1243. - PubMed
    1. Kroeger KM, Muhammad AK, Baker GJ, et al. Gene therapy and virotherapy: novel therapeutic approaches for brain tumors. Discov Med. 2010;10(53):293–304. - PMC - PubMed